Jozefien De Geyter

Jozefien De Geyter

Auto-generated profile, based on publicly available information

Jozefien De Geyter

Laboratory of Molecular Bacteriology, Rega Institute for Medical Research, KU Leuven, Belgium

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2016 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
ATAlexandra Tsirigotaki
Alexandra Tsirigotaki
JGJozefien De Geyter
Jozefien De Geyter
NŠNikolina Šoštaric´
Nikolina Šoštaric´
Tassos EconomouTassos Economou
Tassos Economou
SKSpyridoula Karamanou
Spyridoula Karamanou

26 July 2016 in Nature Microbiology
Verified
Journal Article
Closed access
JGJozefien De Geyter
Jozefien De Geyter
ATAlexandra Tsirigotaki
Alexandra Tsirigotaki
GOGeorgia Orfanoudaki
Georgia Orfanoudaki
VZValentina Zorzini
Valentina Zorzini
Tassos EconomouTassos Economou
Tassos Economou
SKSpyridoula Karamanou
Spyridoula Karamanou

17 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MHMohamed Belal Hamed
Mohamed Belal Hamed
EBEwa Burchacka
Ewa Burchacka
LALiselotte Angus
Liselotte Angus
AMArnaud Marchand
Arnaud Marchand
JGJozefien De Geyter
Jozefien De Geyter
Tassos EconomouTassos Economou
Tassos Economou
The increasing problem of bacterial resistance to antibiotics underscores the urgent need for new antibacterials. The Sec preprotein export pathway is an attractive potential alternative target. It is essential for bacterial viability and includes components that are absent from eukaryotes. Here we used a new high throughput in vivo screen based on the secretion and activity of alkaline phosphatase (PhoA), a Sec-dependent secreted enzyme that becomes active in the periplasm. The assay was optimized for a luminescence-based substrate and was used to screen a ~240K small molecule compound library. After hit confirmation and analoging, fourteen HTS secretion inhibitors (HSI), belonging to 8 structural classes, were identified (IC 50 <60 μM). The inhibitors were also evaluated as antibacterials against 19 Gram − and Gram + bacterial species (including those from the WHO top pathogens list). Seven of them, HSI#6, 9; HSI#1, 5, 10 and HSI#12, 14 representing three structural families were microbicidals. HSI#6 was the most potent (IC 50 of 0.4-8.7 μM), against 13 species of both Gram − and Gram + bacteria. HSI#1, 5, 9 and 10 inhibited viability of Gram + bacteria with IC 50 ~6.9-77.8 μM. HSI#9, 12 and 14 inhibited viability of E. coli strains with IC 50 <65 μM. Moreover, HSI#1, 5 and 10 inhibited viability of an E. coli strain missing TolC to improve permeability with IC 50 4-14 μM, indicating their inability to penetrate the outer membrane. In vitro assays revealed that antimicrobial activity was not related to inhibition of the SecA component of the translocase and hence HSI molecules may target new unknown components that affect secretion. The results provide proof of principle for our approach, and new starting compounds for optimization.